Discover if this is a suitable investor for your startup. If they are we'll make a warm introduction for free. Otherwise, we'll connect you with matching investors.
Nodenza Venture Partners is a venture capital organization founded by a team of experienced life sciences entrepreneurs, founders, and leaders. Established in New York, NY, the firm is dedicated to seeking and investing in disruptive technologies and therapies that promise significant benefits for patients. The firm operates from its office located at 228 Park Ave S, PMB 67135, New York, NY 10003-1502.
Although specific quantitative data regarding fund size, portfolio count, or team size is not available, Nodenza's focus on the life sciences sector positions it as a key player in the investment landscape. The firm has recently expanded its advisory board with the appointment of Paul J. Sekhri, an industry expert, indicating a commitment to enhancing its strategic capabilities and network within the life sciences community.
Nodenza Venture Partners concentrates its investments on the clinical and product launch value inflection points within the life sciences value chain. This focus allows the firm to target critical stages where disruptive technologies and therapies can make a significant impact. The organization aims to facilitate life-changing treatments for patients and physicians through its investments.
The firm is geographically concentrated in North America, aligning its investment strategy with the region's robust life sciences ecosystem. Nodenza seeks to partner with startups that are developing innovative solutions in the biotech and healthcare sectors, emphasizing the importance of disruptive technologies that can transform patient care.
Paul J. Sekhri, Advisory Board Member: Paul has extensive experience in the life sciences sector, having held leadership roles in various biotech companies. His expertise includes strategic development and commercialization of innovative therapies.
Founders interested in pitching Nodenza should send their proposals via email to info@nodenza.com. It is essential to include a comprehensive overview of the startup, the technology or therapy being developed, and the anticipated impact on patient care.
In February 2026, Nodenza Venture Partners announced the appointment of Paul J. Sekhri to its advisory board, enhancing its strategic capabilities in the life sciences sector. The firm also participated in several industry conferences, including the TRS and NYS Emerging Manager Conferences and the Texas Capital Winter Family Office Summit, indicating its active engagement with the life sciences community.
What are Nodenza's investment criteria?
Nodenza focuses on investing in disruptive life sciences technologies and therapies at critical clinical and product launch stages. The firm looks for innovations that have the potential to deliver significant benefits to patients and physicians.
How can I pitch Nodenza?
Founders can reach out to Nodenza via email at info@nodenza.com. It is advisable to include a detailed overview of the technology or therapy, the stage of development, and the potential impact on patient care in the pitch.
What makes Nodenza different from other VCs?
Nodenza's unique focus on the life sciences sector, particularly at critical clinical and product launch stages, sets it apart. The firm is committed to enabling life-changing treatments, which reflects its deep understanding of the life sciences value chain.
What is Nodenza's geographic scope?
The firm primarily invests in North America, concentrating on the life sciences ecosystem within this region.
What kind of post-investment involvement does Nodenza have?
While specific details on post-investment involvement are not disclosed, the firm's focus on critical stages suggests an active role in guiding portfolio companies through their clinical and product launch processes.
What is the typical check size for Nodenza's investments?
Specific check size information is not available, but Nodenza's focus on critical stages implies that it invests at significant points in the development of life sciences technologies.
All trademarks, logos and brand names are the property of their respective owners. All company, product and service names used in this website are for identification purposes only. Use of these names, trademarks, and brands does not imply endorsement.